Amin Nassar
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Amin Nassar
Jul 6, 2024, 04:48 |
Insight
Amin Nassar: Our review on small cell lung cancer is out in Nature Reviews Clinical Oncology
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X: “So happy to…
Apr 5, 2024, 07:53 |
Blog
Rafeh Naqash: Couldn’t be more happy to see this project led by the one and only Amin Nassar to be selected for Rapid Oral ASCO24
Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Center, shared a post on X:…
Feb 7, 2024, 12:46 |
Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
Feb 1, 2024, 14:12 |
Blog
Amin Nassar: Our Multicenter Retrospective Cohort Study' is now out in JTO!
Amin Nassar, Hematology/oncology fellow at Yale University, shared a post on X/Twitter: "Pumped to share…
Nov 27, 2023, 16:52 |
Insight
Rafeh Naqash: Important data in the field of toxicities
Quoting Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Center, on X/Twitter: ''Hot off…
All:
5
Posts:
1 - 100
Michael Douglas: The Untold Story of His Battle Against Cancer
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Kimryn Rathmell: Principles that have kept me going as a Physician Scientist
Amazing Results! President Lynn M. Schuchter on ASCO 2024
Facebook
RSS Feed
Twitter
Linkedin
Youtube